Is neratinib (neratinib) a targeted drug or a chemotherapy drug?

Neratinib (Neratinib) is a targeted drug rather than a traditional chemotherapy drug. Targeted drugs are a class of drugs that inhibit tumor growth and spread by acting on specific molecular targets in cancer cells. In contrast, chemotherapy drugs inhibit tumor growth by killing rapidly dividing cells, including cancer cells and normal cells.

Neratinib is a targeted drug whose mechanism of action is mainly to exert therapeutic effects by inhibiting the growth signaling pathways of tumor cells. It belongs to a class of drugs called tyrosine kinase inhibitors, which target the human epidermal growth factor receptor (HER2). HER2 is a receptor tyrosine kinase. Overexpression or abnormal activation of HER2 has been confirmed to be related to the occurrence and development of various cancers, especially breast cancer. Neratinib (neratinib) can inhibit the activity of HER2 and other related receptors, thereby blocking the proliferation, growth and survival of tumor cells.

Compared with chemotherapy drugs, targeted drugs have a more specific effect and can act on cancer cells more accurately and selectively, thereby reducing damage to normal cells and reducing the incidence of adverse reactions. In addition, targeted drugs often provide longer-lasting effects and have better therapeutic effects on some resistant tumors.

However, although neratinib is a targeted drug, it may still cause some adverse reactions, including but not limited to digestive system problems such as diarrhea, rash, nausea, and vomiting, as well as other common discomforts such as fatigue and headache. Therefore, during treatment with neratinib (neratinib), patients still need to be closely monitored and managed for possible adverse reactions to ensure optimal treatment effects and patient quality of life.